{"schema_version":"secwatch.filing_event.v1","accession":"0001808665-22-000068","form_type":"8-K","ticker":"ASRT","cik":"0001808665","company_name":"Assertio Holdings, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.237735+00:00","generated_at":"2026-06-22T04:19:49.835551+00:00","sec_items":["2.02","5.03","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Assertio Q3 net product sales up 32% YoY to $34.3M; raises FY2022 guidance","bullets":["Net product sales $34.3M (+32% YoY); GAAP net income $4.2M vs $3.7M; adjusted EBITDA $21.4M (+36%).","Debt refinanced: $70M 6.5% convertible notes due 2027 replace $59M 13% senior notes, reducing cost and extending maturity.","Exclusive Sympazan license for $9M upfront; adds ~$1M sales in Q4, new patent to 2039; expects $4-4.5M EBITDA annually.","FY2022 guidance raised: net product sales >$141M (prior $129-137M), adjusted EBITDA >$86M (prior $73-79M).","Cash $64.8M at quarter end; generated $10M operating cash flow, 6th consecutive positive quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001808665-22-000068","json":"https://secwatch.observer/filing/0001808665-22-000068.json","markdown":"https://secwatch.observer/filing/0001808665-22-000068.md","text":"https://secwatch.observer/filing/0001808665-22-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808665/000180866522000068/0001808665-22-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808665/000180866522000068/asrt-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:19:49.835551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6c3377d8c13d52f69d1cccf03ca626b39c79b179","claim":"Assertio Holdings, Inc. reported the three and nine months ended September 30, 2022 results: revenue $ 34.3, net income $ 4.2, EPS $ 0.08. Guidance raised.","evidence_excerpt":"Highlights (unaudited): Three Months Ended September 30, Nine Months Ended September 30, (in millions, except per share amounts) 2022 2021 2022 2021 Net Product Sales (GAAP) $ 34.3 $ 26.0 $ 105.3 $ 77.3 Net Income (loss) (GAAP) $ 4.2 $ 3.7 $ 21.1 $ (5.9) Earnings (loss) Per Share (GAAP) $ 0.08 $ 0.08 $ 0.42 $ (0.14) Adjusted EBITDA (Non-GAAP) 1 $ 21.4 $ 15.8","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808665/000180866522000068/0001808665-22-000068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2022"},{"label":"Revenue","value":"$ 34.3"},{"label":"Net income","value":"$ 4.2"},{"label":"EPS","value":"$ 0.08"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c957d45fedc558dea2854c938b37d184f7a2d05e","claim":"Assertio Holdings, Inc.: Amended and restated bylaws to implement universal proxy rules and update DGCL provisions (effective 2022-11-02).","evidence_excerpt":"On November 2, 2022, the Board of Directors of the Company approved and adopted amended and restated bylaws of the Company (the \"Amended and Restated Bylaws\"), which became effective as of such date.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808665/000180866522000068/0001808665-22-000068-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-11-02"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}